EBFI Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

被引：0

作者：

Escherich, Carolin S. ^{[1
]}

Li, Zhenhua ^{[2
]}

Barnett, Kelly R. ^{[1
]}

Li, Yizhen ^{[1
]}

Walker, Megan ^{[1
]}

Yang, Wenjian ^{[2
]}

Huang, Xin ^{[1
]}

Yu, Jiyang ^{[1
]}

Stock, Wendy ^{[3
]}

Paietta, Elisabeth ^{[4
]}

Konopleva, Marina ^{[5
]}

Kornblau, Steven M. ^{[6
]}

Litzow, Mark R. ^{[7
]}

Inaba, Hiroto ^{[1
]}

Pui, Ching-Hon ^{[1
]}

Loh, Mignon L. ^{[8
]}

Savic, Daniel ^{[1
]}

Yang, Jun J. ^{[1
]}

机构：

[1] St Jude Childrens Res Hosp, Memphis, TN USA

[2] St Jude Childrens Res Hosp, Dept Pharm & Pharmaceut Sci, Memphis, TN USA

[3] Univ Chicago, Chicago, IL USA

[4] Montefiore Med Ctr, Dept Oncol, Bronx, NY USA

[5] Albert Einstein Coll Med, Bronx, NY USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA

[7] Mayo Clin, Div Hematol, Rochester, MN USA

[8] Univ Washington, Seattle Childrens Hosp, Ben Towne Ctr Childhood Canc Res, Fred Hutch Canc Ctr, Seattle, WA USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-198800

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：830 / 831

页数：2

共 50 条

[31] Inotuzumab-ozogamicin/rituximabLack of efficacy
Reactions Weekly, 2024, 2001 (1) : 178 - 178
[32] Inotuzumab ozogamicin as novel therapy in lymphomas
Wong, Bryan Y.
Dang, Nam Hoang
EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (08) : 1251 - 1258
[33] Inotuzumab Ozogamicin: First Pediatric Approval
Dhillon, Sohita
PEDIATRIC DRUGS, 2024, 26 (04) : 459 - 467
[34] Inotuzumab ozogamicin in acute lymphoblastic leukaemia
Gourd, Elizabeth
LANCET ONCOLOGY, 2019, 20 (05): : E248 - E248
[35] Inotuzumab Ozogamicin: First Global Approval
Lamb, Yvette N.
DRUGS, 2017, 77 (14) : 1603 - 1610
[36] Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia
Kohso, Atsushi
Toyoda, Hidemi
Hanaki, Ryo
Niwa, Kaori
Okumura, Yosuke
Morimoto, Mari
Ito, Takahiro
Hirayama, Masahiro
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (02) : 276 - 280
[37] Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
Amandeep Aujla
Ravijot Aujla
Delong Liu
Biomarker Research, 7
[38] Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions
Kantarjian, Hagop M.
Boissel, Nicolas
Papayannidis, Cristina
Luskin, Marlise R.
Stelljes, Matthias
Advani, Anjali S.
Jabbour, Elias J.
Ribera, Josep-Maria
Marks, David I.
CANCER, 2024, 130 (21) : 3631 - 3646
[39] Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
Aujla, Amandeep
Aujla, Ravijot
Liu, Delong
BIOMARKER RESEARCH, 2019, 7 (1)
[40] Dose Optimization of Inotuzumab Ozogamicin in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Deangelo, Daniel J.
Chen, Ying
Cassaday, Ryan D.
Hibma, Jennifer
Yang, Derek Z.
Garrett, May
Zhang, Fan
Dimitrov, Svetoslav H.
Vandendries, Erik
Kantarjian, Hagop M.
BLOOD, 2024, 144 : 732 - 733

← 1 2 3 4 5 →